Eleven Months After the HRT 'Black Box' Came Off: What the New Labels Say, and What They Leave Out

For about twenty years, the first thing many women learned about menopause hormone therapy was that it came with a warning in a black box. Then, in November 2025, the FDA said it would start taking the most alarming parts of that warning away, and a lot of group chats, comment sections and waiting rooms heard it as "HRT is safe now." That is not what the agency said, and it is not what the experts quoted in the coverage said either. Eleven months on, the useful question is not whether to be afraid or relieved, but what exactly changed on the label, what stayed, and what a woman should bring to an appointment now that the conversation has been reopened.

What the FDA actually did

On November 10, 2025, the FDA announced that it was initiating the removal of the boxed warnings from menopausal hormone therapy products, following a review of the scientific literature. On February 12, 2026, it approved labeling changes to the first six products, which include products from each of the four categories of therapy: systemic combination therapy of estrogen and progestogen, systemic estrogen alone, systemic progestogen for women with a uterus who use systemic estrogen, and topical vaginal estrogen. In those six labels, the risk statements about cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning, the agency's most prominent safety statement. The FDA said 29 drug companies had submitted proposed label changes at its request, so six labels in February were the first batch, not the whole market.

That detail matters at the pharmacy counter. If your prescription is for a product that has not yet had its label updated, the old boxed warning may still be on the paper in the box. The FDA keeps a page of menopausal hormone therapies with updated prescribing information, and it encourages women to read the label itself, not a summary of it.

What the warning still says

The change was not a clean sweep. According to Breastcancer.org's reading of the announcement, the FDA will still warn of the risk of uterine and endometrial cancer associated with estrogen-only therapy, which is typically prescribed to women who have had a hysterectomy. For women with a uterus, estrogen is normally paired with a progestogen for exactly that reason. The agency also did not say that hormone therapy is risk-free, and the label still carries information on risks and on who should not take it, so "no black box" should not be read as "no risks." A boxed warning is the agency's loudest way of flagging a risk, and removing parts of it changes how loudly a risk is stated, not who is eligible for a prescription or how a clinician should weigh the evidence for an individual patient.

It also helps to know where the original warning came from. The FDA first applied the boxed warning to hormone therapy products in 2003, and, as Breastcancer.org explains, findings from the Women's Health Initiative, the longest and largest study of HRT so far, informed that decision. The studies since then are the reason the agency now says the original warning overstated some risks.

The case the FDA is making

In its February statement, the FDA argued that hormone therapy is under-used. It said that about 41 million U.S. women were aged 45 to 64 in 2020, yet only about 2 million women aged 46 to 65 received a hormone-therapy prescription, which works out, by our rough division of the two figures, to around one in twenty, although the age bands differ slightly. It also said that randomized studies show that women who start HRT within 10 years of the onset of menopause, generally before age 60, have a reduction in all-cause mortality and fractures. That is the "timing" idea, and it is the part of the argument that most clinicians interviewed in the coverage accept: starting earlier in the transition, at lower doses, looks different from starting in your late sixties. Breastcancer.org's experts add that the risk of breast cancer increases when people start hormone therapy after the age of 60, and Dr. Thomas recommends the lowest dose for the shortest time possible to keep that risk down. Two things can be true at once: the old warning may have frightened women away from a treatment that would have helped them, and the new enthusiasm may do the opposite for women who should think twice. Neither message fits every woman, and a label cannot decide that for her.

The approved uses are the ones women actually notice day to day: moderate to severe hot flashes and night sweats, vaginal dryness and discomfort, and prevention of bone loss. For women whose symptoms are wrecking their sleep or their work, those are not minor benefits.

Where the experts split

The disagreement is about tone, not about the data. Dr. Lisa Larkin, an internal medicine and women's health physician speaking at a Breastcancer.org session, described a pendulum swing: from overemphasizing the risks and ignoring the benefits to overemphasizing the benefits and minimizing the risks. She said she was particularly worried about the impact of that messaging on breast cancer survivors, where the data are unclear. Dr. Parijatham Thomas of MD Anderson called the decision very nuanced and personalized, and said it should be made with an oncologist and a gynecologist.

Here is where the nuance sits, according to the experts quoted by Breastcancer.org:

So the new label does not erase the conversation; it asks for a better one.

If hormones are not for you

The FDA approved fezolinetant (Veozah) in 2023 as the first non-hormonal pill for moderate to severe hot flashes, and, according to Breastcancer.org, approved elinzanetant (Lynkuet) for hot flashes in the fall of 2025. These are options for women who cannot or do not want to use hormones, and they are worth raising in the same appointment, since a plan that compares both is better than one that assumes hormones are the only route.

Five things to bring to the appointment

Skip the screenshot of the headline and bring the label instead. It is public, it is searchable on the FDA's site, and it is the only version of the story that cannot change between the group chat and the clinic.

This is general information, not medical advice. Rules and labels described here are those of the U.S. FDA; other countries' regulators set their own.